Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Journal: The Journal of rheumatology
Published: December 18, 2017
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.
Journal: RMD open
Published: November 13, 2015
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Journal: The Journal of rheumatology
Published: March 04, 2014
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Journal: Annals of the rheumatic diseases
Published: August 22, 2013
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Journal: Arthritis and rheumatism
Published: May 09, 2012
Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1.
Journal: PloS one
Published: April 25, 2012
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
Journal: Rheumatology (Oxford, England)
Published: February 21, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026